News | Oncology Diagnostics | October 30, 2017

Laser Scanner Detects Skin Cancer in Less Than 30 Seconds

A team of European scientists has developed the world’s first cancer scanner that detects blood vessels grown by a malignant melanoma with an infrared laser beam in 30 seconds

Laser Scanner Detects Skin Cancer in Less Than 30 Seconds

Image courtesy of VivoSight

cancer detection scanning patient

Image courtesy of VivoSight

 Photonics VivoSightDX OCT cancer detection screen

Image courtesy of VivoSight

October 30, 2017 — Current skin cancer diagnosis can last a number of weeks and be very upsetting. However, a new imaging system developed by a group of European scientists could dramatically speed up the process and reduce the need for debilitating sentinel-lymph node biopsies by placing real-time cancer diagnosis in the hands of a dermatologist.

Multiple stages of skin cancer diagnosis can involve visiting a GP, being sent to a dermatologist for a skin biopsy, waiting for laboratory analysis, having a sentinel lymph node biopsy under general anaesthetic, and then having more tests if the cancer has spread.

Now, using a handheld laser, a specialist can actually see under the skin at depths of 1 mm by creating a 3-D color image of the microscopic blood vessels in a process that takes around 30 seconds.

Employing a new and advanced version of optical coherence tomography (OCT), a photonics technique more commonly used in retina scans, the scanner captures 3-D images of the micro-structures under the skin with a harmless infrared laser beam.

Since melanomas need oxygen to grow and survive, they grow their own blood vessels. As the cancer develops and becomes more malignant, they become increasingly distorted and malformed, differing in appearance from healthy vessels.

Being able to detect and see these vessels in a suspicious lesion in real time has never been possible, until now, opening the possibility for dermatologists to make treatment decisions in an unrivalled timeframe.

Over 55,500 people in the world died from malignant melanoma of the skin in 2012 alone. While 2,459 deaths from melanoma skin cancer were recorded in the United Kingdom in 2014, an estimated 9,730 people will die of melanoma in the United States in 2017.

Melanomas produce their own blood vessels to feed and grow the tumor, so by revealing the microstructures in 3-D pictures the scanner show doctors how the cancer has developed.

A specialist can potentially determine on the spot, whether simply cutting it out is sufficient for a cure or whether further treatment with cancer drugs will be needed.

With their new device called VivoSight on the market, the European team ADVANCE (Automatic Detection of VAscular Networks for Cancer Evaluation) is aiming to reduce the time for treatment decision from a number of weeks to a matter of seconds, while removing the invasive nature of the appointment.

U.K. project leader Jon Holmes of Michelson Diagnostics Ltd, a key partner in the ADVANCE consortium, explained, “Every melanoma above a certain thickness could have spread to other parts of the body. At present, all patients with such melanomas have to wait for a sentinel lymph node biopsy performed in a hospital under general anesthesia to find out if it is spreading. This can take weeks to perform, is very expensive and can be debilitating for the patient.”

The ADVANCE team has employed a variant of OCT in its scanner called speckle-variance OCT or dynamic OCT (D-OCT), an advancement of OCT that is ideal for capturing movement.

Studying the ‘speckle’ or flicker of light patterns created by moving blood cells, the imaging device takes around four frames per second and compiles the images so that a clinician may tell where something has moved on the image from frame to frame.

“Using D-OCT we can see movement of blood against the solid tissue structures, something we have never been able to do before in a clinical setting. It’s like looking out at night and seeing cars’ headlights flowing along a motorway, only at depths of nanometers under the skin,” said Holmes.

While a sentinel node biopsy can cost in excess of €10,000 (~$13,000 U.S.), and with many hospitals performing hundreds per year, there is a growing concern and a need to find an alternative when over 80 percent of these operations turn out to be clear of any malignant growth, according to Holmes.

As well as its use in skin cancer diagnosis, the ability to see blood vessel networks with the ADVANCE technology has created a number of useful spin-off benefits.

“The scanner can image the blood vessels in healing wounds. This may have application for treatment of leg and foot chronic ulcers, when doctors want to know whether a wound is healing or requires a change in treatment, potentially reducing the number of amputations,” said Holmes. He added,

“ADVANCE technology may also help with burn victims, being able to give a doctor a quicker response time than the standard 15 days to determine whether a patient’s skin is healing and whether or not to give a skin graft.”

For more information: www.photonics21.org

Related Content

Videos | Radiation Therapy | February 15, 2019
ITN Associate Editor Jeff Zagoudis speaks with Vinai Gondi, M.D., director of research and CNS neuro-oncology at the
Synopsys Releases Simpleware ScanIP Medical Software for 3-D Printing
Technology | Medical 3-D Printing | February 14, 2019
Smart technology company Synopsys recently announced the release of the Synopsys Simpleware ScanIP Medical edition for...
Medivis Launches SurgicalAR Augmented Reality Platform
Technology | Advanced Visualization | February 14, 2019
Medical imaging and visualization company Medivis officially unveiled SurgicalAR, its augmented reality (AR) technology...
Micro-Ultrasound and Artificial Intelligence Combining to Detect Prostate Cancer
News | Prostate Cancer | February 12, 2019
Cambridge Consultants has partnered with Exact Imaging, makers of the ExactVu micro-ultrasound platform, as the two...
Standards-based interoperability is the key to the use of components critically important to Vital Images’ vision of enterprise imaging

Standards-based interoperability is the key to the use of components critically important to Vital Images’ vision of enterprise imaging. Graphic courtesy of Vital Images

Feature | Artificial Intelligence | February 11, 2019 | By Greg Freiherr
Vital Images has reconciled its vision of the distant future with near term reality.
Fujifilm Launches Latest Synapse 3D Version at HIMSS 2019

The new Intravoxel Incoherent Motion (IVIM) MR application in Synapse 3D

Technology | Advanced Visualization | February 08, 2019
Fujifilm Medical Systems U.S.A. will debut the latest version of its Synapse 3D solution at the Healthcare Information...
Sponsored Content | Videos | Information Technology | February 07, 2019
In this video Johann Fernando, Ph.D., Chief Operating Officer of...
Oxford University Hospitals Employs Barco Synergi for Multi-disciplinary Cancer Conferences
News | Oncology Diagnostics | February 06, 2019
Oxford University Hospitals (OUH) is trialing clinical collaboration technology from Barco for its Multi-disciplinary...
Sponsored Content | Videos | Artificial Intelligence | February 01, 2019
Artificial intelligence can do more than assist in the interpretation of patient images.
Videos | Lung Cancer | January 29, 2019
Gregory Videtic, M.D., staff physician in radiation oncology at the Cleveland Clinic, and David Johnstone, M.D., prof